• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Efficacy of stereotactic ablative radiotherapy (SABR) during anti-PD-1 in oligoprogressive non-small cell lung cancer and melanoma-a prospective multicenter observational study pointing out new unmet needs.

作者信息

Damen Pim J J, Verhoeff Joost J C

机构信息

Department of Radiation Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.

出版信息

Transl Cancer Res. 2023 Mar 31;12(3):688-691. doi: 10.21037/tcr-22-2841. Epub 2023 Feb 27.

DOI:10.21037/tcr-22-2841
PMID:37033340
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10080467/
Abstract
摘要

相似文献

1
Efficacy of stereotactic ablative radiotherapy (SABR) during anti-PD-1 in oligoprogressive non-small cell lung cancer and melanoma-a prospective multicenter observational study pointing out new unmet needs.立体定向消融放疗（SABR）联合抗程序性死亡蛋白1（PD-1）治疗寡进展性非小细胞肺癌和黑色素瘤的疗效——一项指出新的未满足需求的前瞻性多中心观察性研究
Transl Cancer Res. 2023 Mar 31;12(3):688-691. doi: 10.21037/tcr-22-2841. Epub 2023 Feb 27.
2
tereotactic Ablative Radiotherapy for oligo-progressive disease refractory to systemic therapy in Non-Small Cell Lung Cancer: A registry-based phase II randomized trial (SUPPRESS-NSCLC).立体定向消融放疗治疗非小细胞肺癌中对全身治疗难治的寡进展性疾病：一项基于注册登记的II期随机试验（SUPPRESS-NSCLC）。
Clin Transl Radiat Oncol. 2022 Jan 5;33:115-119. doi: 10.1016/j.ctro.2021.12.008. eCollection 2022 Mar.
3
Combination of SABR With Anti-PD-1 in Oligoprogressive Non-Small Cell Lung Cancer and Melanoma: Results of a Prospective Multicenter Observational Study.SABR 联合抗 PD-1 在寡进展性非小细胞肺癌和黑色素瘤中的应用：一项前瞻性多中心观察性研究的结果。
Int J Radiat Oncol Biol Phys. 2022 Nov 15;114(4):655-665. doi: 10.1016/j.ijrobp.2022.05.013. Epub 2022 May 18.
4
Long-term Local Control and Overall Survival After Radiotherapy in Oligoprogressive Patients During Treatment With Checkpoint Inhibitors.在接受检查点抑制剂治疗期间寡进展患者接受放疗后的长期局部控制和总体生存。
Anticancer Res. 2022 Oct;42(10):4795-4804. doi: 10.21873/anticanres.15984.
5
Maximizing Benefits from Maintenance Pemetrexed with Stereotactic Ablative Radiotherapy in Oligoprogressive Non-Squamous Non-Small Cell Lung Cancer.在寡进展性非鳞状非小细胞肺癌中，培美曲塞维持治疗联合立体定向消融放疗实现效益最大化。
Case Rep Oncol. 2016 Aug 17;9(2):474-480. doi: 10.1159/000448804. eCollection 2016 May-Aug.
6
Stereotactic Ablative Radiotherapy Combined with Immune Checkpoint Inhibitors Reboots the Immune Response Assisted by Immunotherapy in Metastatic Lung Cancer: A Systematic Review.立体定向消融放疗联合免疫检查点抑制剂通过免疫治疗在转移性肺癌中重新激活免疫反应：系统评价。
Int J Mol Sci. 2019 May 2;20(9):2173. doi: 10.3390/ijms20092173.
7
PD-1 Restrains Radiotherapy-Induced Abscopal Effect.程序性死亡蛋白1抑制放射治疗诱导的远隔效应。
Cancer Immunol Res. 2015 Jun;3(6):610-9. doi: 10.1158/2326-6066.CIR-14-0138. Epub 2015 Feb 19.
8
Oligometastatic non-small cell lung cancer: a narrative review of stereotactic ablative radiotherapy.寡转移非小细胞肺癌：立体定向消融放疗的叙述性综述。
Ann Palliat Med. 2021 May;10(5):5944-5953. doi: 10.21037/apm-20-1409. Epub 2021 Feb 23.
9
Stereotactic ablative radiotherapy for acquired resistance to EGFR therapy in metastatic non-small cell lung cancer.立体定向消融放疗用于转移性非小细胞肺癌对表皮生长因子受体治疗的获得性耐药
Front Oncol. 2023 Jan 16;12:1092875. doi: 10.3389/fonc.2022.1092875. eCollection 2022.
10
Stereotactic ablative radiotherapy versus standard radiotherapy in stage 1 non-small-cell lung cancer (TROG 09.02 CHISEL): a phase 3, open-label, randomised controlled trial.立体定向消融放疗与标准放疗治疗Ⅰ期非小细胞肺癌（TROG 09.02 CHISEL）：一项 III 期、开放性标签、随机对照临床试验。
Lancet Oncol. 2019 Apr;20(4):494-503. doi: 10.1016/S1470-2045(18)30896-9. Epub 2019 Feb 12.

引用本文的文献

1
Translational Frontiers and Clinical Opportunities of Immunologically Fitted Radiotherapy.免疫适配放疗的转化前沿和临床机遇。
Clin Cancer Res. 2024 Jun 3;30(11):2317-2332. doi: 10.1158/1078-0432.CCR-23-3632.
2
Pembrolizumab monotherapy for non-small cell lung cancer (NSCLC): can patient stratification be improved in the UK Tayside population? A retrospective cohort study.帕博利珠单抗单药治疗非小细胞肺癌（NSCLC）：在英国泰赛德人群中是否可以改善患者分层？一项回顾性队列研究。
BMJ Open. 2023 Nov 21;13(11):e076715. doi: 10.1136/bmjopen-2023-076715.

本文引用的文献

1
Long-term Local Control and Overall Survival After Radiotherapy in Oligoprogressive Patients During Treatment With Checkpoint Inhibitors.在接受检查点抑制剂治疗期间寡进展患者接受放疗后的长期局部控制和总体生存。
Anticancer Res. 2022 Oct;42(10):4795-4804. doi: 10.21873/anticanres.15984.
2
Combination of SABR With Anti-PD-1 in Oligoprogressive Non-Small Cell Lung Cancer and Melanoma: Results of a Prospective Multicenter Observational Study.SABR 联合抗 PD-1 在寡进展性非小细胞肺癌和黑色素瘤中的应用：一项前瞻性多中心观察性研究的结果。
Int J Radiat Oncol Biol Phys. 2022 Nov 15;114(4):655-665. doi: 10.1016/j.ijrobp.2022.05.013. Epub 2022 May 18.
3
Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trial.度伐利尤单抗联合替西木单抗单药或联合低剂量或亚分次放疗治疗既往 PD-(L)1 治疗耐药的转移性非小细胞肺癌：一项开放标签、多中心、随机、2 期临床试验。
Lancet Oncol. 2022 Feb;23(2):279-291. doi: 10.1016/S1470-2045(21)00658-6. Epub 2022 Jan 13.
4
The Influence of Severe Radiation-Induced Lymphopenia on Overall Survival in Solid Tumors: A Systematic Review and Meta-Analysis.严重放射性所致淋巴细胞减少对实体瘤总生存的影响：系统评价和荟萃分析。
Int J Radiat Oncol Biol Phys. 2021 Nov 15;111(4):936-948. doi: 10.1016/j.ijrobp.2021.07.1695. Epub 2021 Jul 28.
5
The role of local therapy in the treatment of solitary melanoma progression on immune checkpoint inhibition: A multicentre retrospective analysis.局部治疗在免疫检查点抑制治疗单发性黑色素瘤进展中的作用：一项多中心回顾性分析。
Eur J Cancer. 2021 Jul;151:72-83. doi: 10.1016/j.ejca.2021.04.003. Epub 2021 May 7.
6
Radiation for Oligometastatic Lung Cancer in the Era of Immunotherapy: What Do We (Need to) Know?免疫治疗时代寡转移肺癌的放疗：我们（需要）了解什么？
Cancers (Basel). 2021 Apr 28;13(9):2132. doi: 10.3390/cancers13092132.
7
Association of severe lymphopenia and disease progression in unresectable locally advanced non-small cell lung cancer treated with definitive chemoradiation and immunotherapy.在接受根治性放化疗和免疫治疗的不可切除局部晚期非小细胞肺癌中，严重淋巴细胞减少与疾病进展的关联。
Lung Cancer. 2021 Apr;154:36-43. doi: 10.1016/j.lungcan.2021.01.022. Epub 2021 Jan 27.
8
Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.《全球癌症统计数据 2020：全球 185 个国家和地区 36 种癌症的发病率和死亡率估计》。
CA Cancer J Clin. 2021 May;71(3):209-249. doi: 10.3322/caac.21660. Epub 2021 Feb 4.
9
Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer: a pooled analysis of two randomised trials.帕博利珠单抗联合或不联合放疗治疗转移性非小细胞肺癌：两项随机试验的汇总分析。
Lancet Respir Med. 2021 May;9(5):467-475. doi: 10.1016/S2213-2600(20)30391-X. Epub 2020 Oct 20.
10
Pembrolizumab with or without radiation therapy for metastatic non-small cell lung cancer: a randomized phase I/II trial.帕博利珠单抗联合或不联合放射治疗转移性非小细胞肺癌：一项随机 I/II 期试验。
J Immunother Cancer. 2020 Oct;8(2). doi: 10.1136/jitc-2020-001001.